FDA signs off on Merus' first-in-class NRG1+ cancer drug Bizengri after brief delay

Merus’ week keeps getting better. Days after securing a long-awaited commercialization partner for its zenocutuzumab, the drug has crossed the FDA finish line as the first therapy to target cancers that harbor a neuregulin 1 (NRG1) gene fusion.